Successful treatment with Pola-R-mini-CHP for elderly relapsed and refractory mantle cell lymphoma

被引：0
|
作者：
Oka, Satoko [1 ]
Akagi, Yuina [1 ]
Ono, Kazuo [2 ]
机构：
[1] Japanese Red Cross Soc Wakayama Med Ctr, Div Hematol, Wakayama, Wakayama, Japan
[2] Japanese Red Cross Soc Wakayama Med Ctr, Div Pathol, Wakayama, Japan
来源：
ANNALS OF HEMATOLOGY | 2024年 / 103卷 / 12期
关键词：
Mantle cell lymphoma (MCL); Relapse/refractory; Pola-R-mini-CHP;
D O I：
10.1007/s00277-024-06024-z
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：5981 / 5983
页数：3
相关论文
共 50 条
  • [1] Use of R-mini-CHP in combination with polatuzumab vedotin (pola-R-mini-CHP) as the primary treatment in ≥80-year-old cases with diffuse large B-cell lymphoma
    Sekiguchi, Yasunobu
    Tsutsumi, Hiroki
    Gomyo, Ayumi
    Kudo, Masahisa
    Iizaki, Yoshie
    Maseki, Nobuo
    Kawamura, Machiko
    Kobayashi, Kazuhiko
    Nishimura, Yu
    Kanda, Hiroaki
    Nitta, Hideaki
    Noguchi, Masaaki
    Kobayashi, Hirofumi
    JOURNAL OF CLINICAL AND EXPERIMENTAL HEMATOPATHOLOGY, 2023, 63 (04) : 262 - 265
  • [2] Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma
    Tam, Constantine S.
    Opat, Stephen
    Simpson, David
    Cull, Gavin
    Munoz, Javier
    Phillips, Tycel J.
    Kim, Won Seog
    Rule, Simon
    Atwal, Siminder Kaur
    Wei, Rachel
    Novotny, William
    Huang, Jane
    Wang, Michael
    Trotman, Judith
    BLOOD ADVANCES, 2021, 5 (12) : 2577 - 2585
  • [3] Temsirolimus in the treatment of relapsed or refractory mantle cell lymphoma
    Samad, Nousheen
    Younes, Anas
    ONCOTARGETS AND THERAPY, 2010, 3 : 167 - 178
  • [4] Novel Treatment Approaches in Relapsed/Refractory Mantle Cell Lymphoma
    Maddocks, Kami
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S187 - S188
  • [5] Brexucabtagene autoleucel for the treatment of relapsed/refractory mantle cell lymphoma
    Mian, Agrima
    Hill, Brian T.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2021, 21 (04) : 435 - 441
  • [6] Evaluating pirtobrutinib for the treatment of relapsed or refractory mantle cell lymphoma
    Wang, Jacqueline F.
    Wang, Yucai
    EXPERT REVIEW OF HEMATOLOGY, 2024, 17 (10) : 651 - 659
  • [7] Treatment Patterns and Outcomes in Relapsed/Refractory Mantle Cell Lymphoma
    Tawfiq, Reema K.
    Larson, Melissa C.
    Gile, Jennifer Jane
    Bock, Allison M.
    Poonsombudlert, Kittika
    Maliske, Seth M.
    Maurer, Matthew J.
    Cerhan, James R.
    Kabat, Brian
    Smith, Katherine
    Godby, Richard Curtis
    Paludo, Jonas
    Inwards, David J.
    Ayyappan, Sabarish
    Ansell, Stephen M.
    Habermann, Thomas M.
    Witzig, Thomas E.
    Nowakowski, Grzegorz S.
    Farooq, Umar
    Wang, Yucai
    BLOOD, 2022, 140 : 6489 - 6491
  • [8] Temsirolimus In Relapsed and/or Refractory Mantle Cell Lymphoma
    Hoy, Sheridan M.
    McKeage, Kate
    DRUGS, 2010, 70 (14) : 1819 - 1829
  • [9] Management of relapsed/refractory mantle cell lymphoma
    Alzahrani, Musa
    Villa, Diego
    LEUKEMIA & LYMPHOMA, 2024, 65 (08) : 1044 - 1054
  • [10] TemsirolimusIn Relapsed and/or Refractory Mantle Cell Lymphoma
    Sheridan M. Hoy
    Kate McKeage
    Drugs, 2010, 70 : 1819 - 1829
12345